Study Evaluating Multiple Ascending Doses Of ATN-103 In Japanese Subjects With Rheumatoid Arthritis

NCT01007175 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: ATN-103 10 mg q4wks
BIOLOGICAL: ATN-103 30 mg q4wks
BIOLOGICAL: ATN-103 80 mg q4wks
BIOLOGICAL: ATN-103 10 mg q8wks
BIOLOGICAL: ATN-103 80 mg q8wks

Sponsor

Ablynx, a Sanofi company